Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.

Athira Pharma Inc

ATHA
0,558
0,0195 (3,62%)
28 Dic 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
06/12/202423:30GLOBEAthira Pharma Presents Preclinical Data Highlighting..
07/11/202422:10EDGAR2Form 8-K - Current report
07/11/202422:05GLOBEAthira Pharma Reports Third Quarter 2024 Financial Results..
29/10/202405:15EDGAR2Form EFFECT - Notice of Effectiveness
22/10/202413:00GLOBEAthira Pharma to Present Results from Phase 2/3 LIFT-AD..
21/10/202412:24EDGAR2Form S-3 - Registration statement under Securities Act of..
18/10/202422:02EDGAR2Form 8-K - Current report
04/10/202401:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202401:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202401:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202401:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202401:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
17/9/202415:00EDGAR2Form 8-K - Current report
17/9/202415:00GLOBEAthira Pharma to Focus on Advancement of ATH-1105 for the..
06/9/202401:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202401:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202401:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/9/202411:50IHMARKETNEWSNvidia Subpoenaed by DOJ, Athira Pharma Shares Plunge 71%..
03/9/202422:01EDGAR2Form 8-K - Current report
03/9/202422:01GLOBEAthira Pharma Announces Topline Results from Phase 2/3..
09/8/202422:05EDGAR2Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]:..
01/8/202422:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/8/202422:10EDGAR2Form 8-K - Current report
01/8/202422:05GLOBEAthira Pharma Reports Second Quarter 2024 Financial Results..
31/7/202414:05GLOBEAthira Pharma Presents Preclinical Data Demonstrating New..
12/6/202413:00GLOBEAthira to Host Webinar Highlighting Potential for..
11/6/202413:00GLOBEAthira Pharma Completes First Cohort in Phase 1 Clinical..
29/5/202422:05EDGAR2Form 8-K - Current report
29/5/202413:00GLOBEAthira Pharma to Participate in Upcoming June Conferences
25/5/202401:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/5/202400:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/5/202400:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202423:00EDGAR2Form 8-K - Current report
17/5/202423:00GLOBEAthira Pharma Announces Proposed Settlement of Stockholder..
15/5/202422:10EDGAR2Form 8-K - Current report
15/5/202422:05GLOBEAthira Pharma Reports First Quarter 2024 Financial Results..
02/5/202413:00GLOBEAthira Pharma to Participate in Upcoming May Conferences
15/4/202413:00GLOBEAthira Pharma Appoints Javier San Martin, M.D., as Chief..
11/4/202413:00GLOBEAthira Pharma Announces Publication of Preclinical Data..
03/4/202413:00GLOBEAthira Pharma Announces Upcoming Poster Presentation at..
08/3/202413:00GLOBEAthira Pharma Presents Clinical and Preclinical Data..
22/2/202422:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
22/2/202422:10EDGAR2Form 8-K - Current report
22/2/202422:05GLOBEAthira Pharma Reports Full Year 2023 Financial Results and..
16/2/202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202422:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202422:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/2/202422:02GLOBEAthira Pharma Announces Publication in Frontiers in..
08/1/202422:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202422:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 0,5208 Min: 0,52 Max: 0,561
Chiusura: 0,5385

La tua Cronologia

Delayed Upgrade Clock

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network